Phase 1 Prostate Cancer Trial, Recruiting NCT06450106 Sponsor: SURGE Therapeutics Condition: Prostate Cancer
Back to Prostate Cancer

Phase 1 Prostate Cancer Trial, Recruiting

NCT06450106
Recruiting Phase 1 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are male and aged 18 years or older at the time of signing consent
  • People who have a confirmed prostate cancer diagnosis (confirmed through tissue testing) and are scheduled to have their prostate surgically removed within 28 days of the screening visit
  • People whose prostate cancer falls within Grade Group 2 to 5 (a measure of how the cancer cells look under a microscope)
  • People whose general physical health and ability to carry out daily activities meets a certain minimum level, as assessed using a standard medical scale (confirm with trial site)
  • People whose organ function and blood counts are within acceptable ranges at screening
  • People who are able to understand and willing to sign a consent form that has been approved by an ethics review board

Who may not be able to join:

  • People who have another type of invasive cancer, separate from the prostate cancer being studied
  • People for whom doctors expect a drainage tube will need to be used after the prostate removal surgery
  • People who have received any other cancer treatment (such as chemotherapy, immunotherapy, radiation, hormone therapy, or similar treatments) within the 28 days before joining the trial
  • People who have had allergic reactions to substances with a similar makeup to the ingredients in the study treatment, including poloxamer 407 or sodium hyaluronate
  • People who have previously received an organ transplant from another person
  • People who have a history of a condition where the immune system does not work properly from birth or early life (primary immunodeficiency)
  • People whose heart electrical activity measurement (a specific interval measured on a heart tracing) is above a certain level at screening (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 781-605-8632

Australian sites

Australian Prostate Center, Melbourne N., Victoria
Epworth HealthCare, Melbourne N., Victoria

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
SURGE Therapeutics
Registry
ClinicalTrials.gov
Start date
8 May 2025
Est. completion
1 September 2026

Where this trial is recruiting

🇦🇺 Australia 🇺🇸 United States

2 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Incidence of dose-limiting toxicities (DLTs) [Safety and Tolerability]; Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov